Related Experiment Video
Updated: Oct 25, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and
Kristina Lindsley1, Arianna Nevo2, Carmine Colavecchia3
1Evidence Synthesis, IQVIA, Falls Church, Virginia, USA.
Background:
Hemophilia B is a rare, X-linked disorder leading to deficient or dysfunctional clotting factor IX and bleeding complications.
Objectives:
The objective of this systematic review and meta-analysis was to summarize bleeding events in people with hemophilia B of any severity without inhibitors receiving prophylactic factor IX replacement therapies to better understand disease burden and unmet needs.
Methods:
A systematic search was conducted to identify clinical trials and observational studies reporting annualized bleeding rate (ABR), annualized joint bleeding rate, spontaneous bleeding events, traumatic bleeding events, and percentage of patients with zero-bleeding events. Bleeding outcomes were specified as total, treated, or unspecified and analyzed using the random-effects model. Subgroup meta-analyses assessed differences by age, treatment type, follow-up duration, and publication date, when feasible.
Results:
The search yielded 5684 citations; 24 clinical trials and 53 observational studies were included in the meta-analysis. Treated ABR was 2.23 (95% CI, 1.52-3.27) in 13 trials; treated or unspecified ABR was 2.25 (95% CI, 1.67-3.03) in 22 trials. In 48 observational studies, treated or unspecified ABR was 2.08 (95% CI, 1.62-2.66). ABR was generally lower for patients <12 years of age (vs ≥12 years of age) and patients treated with extended half-life (vs standard half-life).
Conclusion:
Results from this meta-analysis reflect advances in hemophilia B treatment, but also highlight unmet needs, with many patients experiencing ≥2bleeding events per year. Inconsistent ABR definitions and variability in follow-up times may introduce heterogeneity in the combined estimates.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management